Search

Your search keyword '"Lalancette, Marc"' showing total 44 results
Start Over Author "Lalancette, Marc"
44 results on '"Lalancette, Marc"'

1. The neurophysiological brain-fingerprint of Parkinson’s disease

Author

Breitner, John, Poirier, Judes, Baillet, Sylvain, Bellec, Pierre, Bohbot, Véronique, Chakravarty, Mallar, Collins, Louis, Etienne, Pierre, Evans, Alan, Gauthier, Serge, Hoge, Rick, Ituria-Medina, Yasser, Multhaup, Gerhard, Münter, Lisa-Marie, Rajah, Natasha, Rosa-Neto, Pedro, Soucy, Jean-Paul, Vachon-Presseau, Etienne, Villeneuve, Sylvia, Amouyel, Philippe, Appleby, Melissa, Ashton, Nicholas, Auld, Daniel, Ayranci, Gülebru, Bedetti, Christophe, Beland, Marie-Lise, Blennow, Kaj, Westman, Ann Brinkmalm, Cuello, Claudio, Dadar, Mahsa, Daoust, Leslie-Ann, Das, Samir, Dauar-Tedeschi, Marina, De Beaumont, Louis, Dea, Doris, Descoteaux, Maxime, Dufour, Marianne, Farzin, Sarah, Ferdinand, Fabiola, Fonov, Vladimir, Gonneaud, Julie, Kat, Justin, Kazazian, Christina, Labonté, Anne, Lafaille-Magnan, Marie-Elyse, Lalancette, Marc, Lambert, Jean-Charles, Leoutsakos, Jeannie-Marie, Mahar, Laura, Mathieu, Axel, McSweeney, Melissa, Meyer, Pierre-François, Miron, Justin, Near, Jamie, NewboldFox, Holly, Nilsson, Nathalie, Orban, Pierre, Picard, Cynthia, Binette, Alexa Pichet, Poline, Jean-Baptiste, Rabipour, Sheida, Salaciak, Alyssa, Settimi, Matthew, Subramaniapillai, Sivaniya, Tam, Angela, Tardif, Christine, Théroux, Louise, Tremblay-Mercier, Jennifer, Tullo, Stephanie, Ulku, Irem, Vallée, Isabelle, Zetterberg, Henrik, Nair, Vasavan, Pruessner, Jens, Aisen, Paul, Anthal, Elena, Barkun, Alan, Beaudry, Thomas, Benbouhoud, Fatiha, Brandt, Jason, Carmo, Leopoldina, Carrier, Charles Edouard, Cheewakriengkrai, Laksanun, Courcot, Blandine, Couture, Doris, Craft, Suzanne, Dansereau, Christian, Debacker, Clément, Desautels, René, Dubuc, Sylvie, Duclair, Guerda, Eisenberg, Mark, El-Khoury, Rana, Faubert, Anne-Marie, Fontaine, David, Frappier, Josée, Frenette, Joanne, Gagné, Guylaine, Gervais, Valérie, Giles, Renuka, Gordon, Renee, Jack, Clifford, Jutras, Benoit, Khachaturian, Zaven, Knopman, David, Kostopoulos, Penelope, Lapalme, Félix, Lee, Tanya, Lepage, Claude, Leppert, Illana, Madjar, Cécile, Maillet, David, Maltais, Jean-Robert, Mathotaarachchi, Sulantha, Mayrand, Ginette, Michaud, Diane, Montine, Thomas, Morris, John, Pagé, Véronique, Pascoal, Tharick, Peillieux, Sandra, Petkova, Mirela, Pogossova, Galina, Rioux, Pierre, Sager, Mark, Saint-Fort, Eunice Farah, Savard, Mélissa, Sperling, Reisa, Tabrizi, Shirin, Tariot, Pierre, Teigner, Eduard, Thomas, Ronald, Toussaint, Paule-Joanne, Tuwaig, Miranda, Venugopalan, Vinod, Verfaillie, Sander, Vogel, Jacob, Wan, Karen, Wang, Seqian, Yu, Elsa, Beaulieu-Boire, Isabelle, Blanchet, Pierre, Bogard, Sarah, Bouchard, Manon, Chouinard, Sylvain, Cicchetti, Francesca, Cloutier, Martin, Dagher, Alain, Degroot, Clotilde, Desautels, Alex, Dion, Marie Hélène, Drouin-Ouellet, Janelle, Dufresne, Anne-Marie, Dupré, Nicolas, Duquette, Antoine, Durcan, Thomas, Fellows, Lesley K., Fon, Edward, Gagnon, Jean-François, Gan-Or, Ziv, Genge, Angela, Jodoin, Nicolas, Karamchandani, Jason, Lafontaine, Anne-Louise, Langlois, Mélanie, Leveille, Etienne, Lévesque, Martin, Melmed, Calvin, Monchi, Oury, Montplaisir, Jacques, Panisset, Michel, Parent, Martin, Pham-An, Minh-Thy, Postuma, Ronald, Pourcher, Emmanuelle, Rao, Trisha, Rivest, Jean, Rouleau, Guy, Sharp, Madeleine, Soland, Valérie, Sidel, Michael, Wing Sun, Sonia Lai, Thiel, Alexander, Vitali, Paolo, da Silva Castanheira, Jason, Wiesman, Alex I., Hansen, Justine Y., and Misic, Bratislav

Published
2024
Full Text
View/download PDF

2. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Author

Dimopoulos, Meletios, San-Miguel, Jesus, Belch, Andrew, White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Ho, P, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan, Sutherland, Heather, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin, Prince, H, Cochrane, Tara, Oriol, Albert, Bahlis, Nizar, Chari, Ajai, ORourke, Lisa, Wu, Kaida, Schecter, Jordan, Casneuf, Tineke, Chiu, Christopher, Soong, David, Sasser, A, Khokhar, Nushmia, Avet-Loiseau, Hervé, and Usmani, Saad

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Neoplasm, Residual, Outcome Assessment, Health Care
Abstract

In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma. We provide one additional year of follow up and include the effect on minimal residual disease and in clinically relevant subgroups. After 25.4 months of follow up, daratumumab plus lenalidomide/dexamethasone prolonged progression-free survival versus lenalidomide/dexamethasone alone (median not reached vs 17.5 months; hazard ratio, 0.41; 95% confidence interval, 0.31-0.53; P12 and ≤12 months and >6 and ≤6 months. No new safety signals were observed. In relapsed/refractory multiple myeloma patients, daratumumab plus lenalidomide/dexamethasone continued to improve progression-free survival and deepen responses versus lenalidomide/dexamethasone. Trial Registration: clinicaltrials.gov identifier: 02076009.

Published
2018

3. Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.

Author

Pelland, Andrée-Anne, Deschênes-Simard, Xavier, Savard, Xavier, Giguère, Philippe, Spillane, David, Barabé, Frédéric, Laroche, Vincent, Munger, Michaël, Gallagher, Geneviève, Marcoux, Nicolas, Cantin, Guy, Chénard-Poirier, Maxime, Delage, Robert, Lalancette, Marc, Veilleux, Olivier, Assouline, Sarit E., and Lemieux, Christopher

Subjects
ACUTE myeloid leukemia, SALVAGE therapy, SEPTIC shock, INTENSIVE care units, FEBRILE neutropenia, STEM cell transplantation
Abstract

This study reports characteristics and outcomes of adults who received Azacitidine-Venetoclax (AZA-VEN) compared to other salvage therapies (NO-AZA-VEN) as first salvage therapy for acute myeloid leukemia (AML). The clinical data of 81 patients with a diagnosis of relapsed or refractory AML were analyzed. The ORR was comparable for both groups (55% vs 57%, p = 0.852). Median OS (6.8 vs 11.2 months, p = 0.053) and median RFS (6.9 vs 11.2 months, p = 0.488) showed a trend in favor of the NO-AZA-VEN group. OS was significantly longer with NO-AZA-VEN for ELN 2022 risk category sub-group, patients under 60 years old, primary AML and for patients who underwent allo-hematopoietic stem cell transplant after salvage therapy. There was no statistical difference in complications of treatment such as febrile neutropenia, intensive care unit stay, septic shock and total parenteral nutrition. Those results do not support the preferential use of AZA-VEN over other regimens in R/R acute myeloid leukemia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.

Author

Tessier, Camille, LeBlanc, Richard, Roy, Jean, Trudel, Sabrina, Côté, Julie, Lalancette, Marc, Boudreault, Jean‐Samuel, Lemieux‐Blanchard, Émilie, Kaedbey, Rayan, and Pavic, Michel

Subjects
PLASMA cell leukemia, PLASMA cell diseases, MULTIPLE myeloma, PROGNOSIS, HEMATOLOGIC malignancies
Abstract

Background: Plasma cell leukemia (PCL) is a rare monoclonal gammopathy, associated with short survival. Because of its very low incidence, only a few cohorts have been reported and thus, information on this disease is scarce. The goal of this study was to better understand the clinical features, prognostic factors, and efficacy of modern treatments in both primary PCL (pPCL) and secondary PCL (sPCL). Methods: We performed a retrospective, multicenter study of patients diagnosed with PCL, defined as circulating plasma cells ≥20% of total leukocytes and/or ≥2 × 109/L. Results: We identified 99 eligible PCL patients, of whom 33 were pPCL and 66 were sPCL. The median progression‐free survival (PFS) to frontline treatment and overall survival (OS) were, respectively, 4.8 (95% CI, 0.4–9.2) and 18.3 months (95% CI, 0.0–39.0) for pPCL and 0.8 (95% CI, 0.5–1.1) and 1.2 months (95% CI, 0.9–1.5) for sPCL (both p < 0.001). We observed no improvement in OS over time (2005–2012 vs. 2013–2020, p = 0.629 for pPCL and p = 0.329 for sPCL). Finally, our data suggested that sPCL originates from a high‐risk multiple myeloma (MM) population with a short OS (median 30.2 months), early relapse after stem cell transplant (median 11.9 months) and a high proportion of patients with multiple cytogenetic abnormalities (36% with ≥2 abnormalities). Conclusions: This study is one of the largest PCL cohorts reported. We are also the first to investigate characteristics of MM before its transformation into sPCL and demonstrate that high‐risk biologic features already present at the time of MM diagnosis. Moreover, our data highlights the lack of improvement in PCL survival in recent years and the urgent need for better treatment options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study.

Author

Morin, Laurence, Grenier, Louis-Philippe, Foucault, Nicolas, Lévesque, Éric, Fabi, François, Langlais, Eve-Lyne, Sebastianelli, Alexandra, Lavoie, Marianne, Lalancette, Marc, Plante, Marie, Singbo, Mahukpe Narcisse Ulrich, and Castonguay, Vincent

Subjects
OVARIAN cancer, PACLITAXEL, TREATMENT effectiveness, DECISION making, CANCER chemotherapy
Abstract

Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these regimens is available to provide objective guidance in clinical decision making. The primary objective of this study was to compare the cumulative dose of paclitaxel delivered using 80 mg/m2/week, administered using either a 3 weeks out of 4 (WP3) or a 4 weeks out of 4 (WP4) regimen. The secondary objective was to evaluate the clinical outcomes associated with both regimens, including efficacy and toxicity parameters. Our retrospective cohort comprised 149 patients harboring platinum-resistant ovarian cancer treated at the CHU de Québec from January 2012 to January 2023. WP3 and WP4 reached a similar cumulative dose (1353.7 vs. 1404.2 mg/m2; p = 0.29). No significant differences in the clinical outcomes were observed. The frequency of dose reduction was significantly higher for WP4 than WP3 (44.7% vs. 4.9%; p < 0.01), mainly due to treatment intolerance from toxicity (34.0% vs. 3.9%; p < 0.01). Our data suggest that a WP3 regimen delivers a similar cumulative dose to WP4, hence offering a better efficacy profile without compromising efficacy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Author

Pelland, Andree-Anne, primary, Savard, Xavier, additional, Barabe, Frederic, additional, Laroche, Vincent, additional, Munger, Michaël, additional, Gallagher, Genevieve, additional, Marcoux, Nicolas, additional, Cantin, Guy, additional, Chénard-Poirier, Maxime, additional, Delage, Robert, additional, Lalancette, Marc, additional, and Lemieux, Christopher, additional

Published
2022
Full Text
View/download PDF

11. Adjuvant treatment for endometrial cancer: Literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)

Author

Almanric, Karine, Boily, Gino, Bouchard, Philippe, Boulanger, Jim, Cournoyer, Ghislain, Couture, Félix, Gervais, Normand, Goulet, Stéphanie, Guay, Marie-Pascale, Kavanagh, Mélanie, Lemieux, Julie, Lespérance, Bernard, Letarte, Nathalie, Morneau, Mélanie, Ouellet, Jean-François, Pineau, Gilles, Rajan, Raghu, Roy, Isabelle, Samson, Benoît, Sidéris, Lucas, Vincent, François, Foster, William, Lalancette, Marc, Van Nguyen-Huynh, Thu, Renaud, Marie-Claude, and Samouëlian, Vanessa

Published
2013
Full Text
View/download PDF

13. Protocoles de traitement : Service d'hémato-oncologie CHU de Québec 2020 Ed. 9

Author

Lalancette, Marc, Lalancette, Marc, Lalancette, Marc, and Lalancette, Marc

Abstract

Cet outil de travail ne doit être utilisé que par des personnes compétentes dans le traitement des cancers et familières avec la chimiothérapie. Les auteurs ne sont en aucun cas responsables des erreurs ayant pu s'y glisser ni de son utilisation par des individus autres que les auteurs. Ce n'est pas un livre de recettes mais bien un document à utiliser dans un contexte de soins globaux. De même, en aucun cas, on ne peut affirmer que les options thérapeutiques doivent se limiter à ce que l'on retrouve dans ce guide.

Published
2020

16. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Author

Monteith, Bethany E., primary, Venner, Christopher P., additional, Cheung, Matthew C., additional, Pater, Joe, additional, Shepherd, Lois, additional, Richardson, Harriet, additional, Reece, Donna, additional, Gul, Engin, additional, Lalancette, Marc, additional, Castonguay, Vincent, additional, Kukreti, Vishal, additional, Tiedemann, Rodger, additional, Phua, Chai, additional, Bhella, Sita, additional, Dudebout, Jill, additional, Sherry, Max, additional, Yen, Hope, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2021
Full Text
View/download PDF

17. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

Author

Venner, Christopher P., primary, LeBlanc, Richard, additional, Sandhu, Irwindeep, additional, White, Darrell, additional, Belch, Andrew R., additional, Reece, Donna E., additional, Chen, Christine, additional, Dolan, Sean, additional, Lalancette, Marc, additional, Louzada, Martha, additional, Kew, Andrea, additional, McCurdy, Arleigh, additional, Monteith, Bethany, additional, Reiman, Tony, additional, McDonald, Gail, additional, Sherry, Max, additional, Gul, Engin, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2021
Full Text
View/download PDF

19. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Author

Crawley, Charles, Szydlo, Richard, Lalancette, Marc, Bacigalupo, Andrea, Lange, Andrzej, Brune, Mats, Juliusson, Gunnar, Nagler, Arnon, Gratwohl, Alois, Passweg, Jakob, Komarnicki, Mieczysław, Vitek, Antonin, Mayer, Jiri, Zander, Axel, Sierra, Jorge, Rambaldi, Alessandro, Ringden, Olle, Niederwieser, Dietger, and Apperley, Jane F.

Published
2005
Full Text
View/download PDF

20. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

Author

Crawley, Charles, Lalancette, Marc, Szydlo, Richard, Gilleece, Maria, Peggs, Karl, Mackinnon, Stephen, Juliusson, Gunnar, Ahlberg, Lucia, Nagler, Arnon, Shimoni, Avichai, Sureda, Anna, Boiron, Jean-Michel, Einsele, Herman, Chopra, Rajesh, Carella, Angelo, Cavenagh, Jamie, Gratwohl, Alois, Garban, Frederic, Zander, Axel, Björkstrand, Bo, Niederwieser, Dietger, Gahrton, Gösta, and Apperley, Jane F.

Published
2005
Full Text
View/download PDF

21. Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Author

Venner, Christopher P, primary, Leblanc, Richard, additional, Sandhu, Irwindeep, additional, White, Darrell J, additional, Belch, Andrew, additional, Reece, Donna E, additional, Chen, Christine I, additional, Dolan, Sean, additional, Lalancette, Marc, additional, Louzada, Martha L, additional, Kew, Andrea, additional, McCurdy, Arleigh, additional, Reiman, Tony, additional, Sherry, Max, additional, McDonald, Gail T., additional, Monteith, Bethany Elaine, additional, Gul, Engin, additional, Chen, Bingshu E., additional, and Hay, Annette E., additional

Published
2019
Full Text
View/download PDF

22. Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)

Author

Monteith, Bethany, primary, Venner, Chritopher, additional, Reece, Donna, additional, Kew, Andrea, additional, Lalancette, Marc, additional, Garland, Jocelyn, additional, Shepherd, Lois, additional, McDonald, Gail, additional, Gul, Engin, additional, Pater, Joe, additional, and Hay, Annette, additional

Published
2019
Full Text
View/download PDF

23. Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN‐003/MYX.1 single arm phase II trial.

Author

Venner, Christopher P., LeBlanc, Richard, Sandhu, Irwindeep, White, Darrell, Belch, Andrew R., Reece, Donna E., Chen, Christine, Dolan, Sean, Lalancette, Marc, Louzada, Martha, Kew, Andrea, McCurdy, Arleigh, Monteith, Bethany, Reiman, Tony, McDonald, Gail, Sherry, Max, Gul, Engin, Chen, Bingshu E., and Hay, Annette E.

Published
2021
Full Text
View/download PDF

26. MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Author

Venner, Christopher P., primary, Leblanc, Richard, additional, Sandhu, Irwindeep, additional, White, Darrell J., additional, Belch, Andrew R, additional, Reece, Donna E, additional, Chen, Christine I, additional, Dolan, Sean, additional, Kew, Andrea, additional, Lalancette, Marc, additional, Louzada, Martha L, additional, McCurdy, Arleigh, additional, McDonald, Gail T., additional, Reiman, Tony, additional, Rodriguez, Laura, additional, Shepherd, Lois E., additional, Gul, Engin, additional, Chen, Bingshu E., additional, and Hay, Annette E, additional

Published
2018
Full Text
View/download PDF

27. Depth of response and MRD with Daratumumab plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX

Author

San-Miguel, Jesus Dimopoulos, Meletios Athanasios Usmani, Saad and Belch, Andrew R. Bahlis, Nizar J. White, Darrell J. and Benboubker, Lofti Cook, Gordon Leiba, Merav Morton, James and Ho, P. Joy Kim, Kihyun Takezako, Naoki Kaufman, Jonathan L. Sutherland, Heather Lalancette, Marc Magen, Hila and Iida, Shinsuke Kim, Jin Seok Prince, H. Miles Cochrane, Tara and Oriol, Albert Chari, Ajai Wu, Kaida Casneuf, Tineke

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2017

28. Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX

Author

Dimopoulos, Meletios Belch, Andrew R. White, Darrell J. and Benboubker, Lofti Cook, Gordon Leiba, Merav Morton, James and Ho, P. Joy Kim, Kihyun Takezako, Naoki San-Miguel, Jesus and Moreau, Philippe Kaufman, Jonathan L. Sutherland, Heather and Lalancette, Marc Magen, Hila Iida, Shinsuke Kim, Jin Seok Prince, H. Miles Cochrane, Tara Oriol, Albert and Chari, Ajai O'Rourke, Lisa Wu, Kaida Casneuf, Tineke and Chiu, Christopher Soong, David Qin, Xiang Sasser, Kate and Khokhar, Nushmia and Dimopoulos, Meletios Belch, Andrew R. White, Darrell J. and Benboubker, Lofti Cook, Gordon Leiba, Merav Morton, James and Ho, P. Joy Kim, Kihyun Takezako, Naoki San-Miguel, Jesus and Moreau, Philippe Kaufman, Jonathan L. Sutherland, Heather and Lalancette, Marc Magen, Hila Iida, Shinsuke Kim, Jin Seok Prince, H. Miles Cochrane, Tara Oriol, Albert and Chari, Ajai O'Rourke, Lisa Wu, Kaida Casneuf, Tineke and Chiu, Christopher Soong, David Qin, Xiang Sasser, Kate and Khokhar, Nushmia

Published
2017

29. Daratumumab, Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM Based on Prior Lines and Treatment Exposure: POLLUX

Author

Dimopoulos, Meletios, primary, Belch, Andrew R., additional, White, Darrell J., additional, Benboubker, Lofti, additional, Cook, Gordon, additional, Leiba, Merav, additional, Morton, James, additional, Ho, P. Joy, additional, Kim, Kihyun, additional, Takezako, Naoki, additional, San-Miguel, Jesus, additional, Moreau, Philippe, additional, Kaufman, Jonathan L., additional, Sutherland, Heather, additional, Lalancette, Marc, additional, Magen, Hila, additional, Iida, Shinsuke, additional, Kim, Jin Seok, additional, Prince, H. Miles, additional, Cochrane, Tara, additional, Oriol, Albert, additional, Chari, Ajai, additional, O'Rourke, Lisa, additional, Wu, Kaida, additional, Casneuf, Tineke, additional, Chiu, Christopher, additional, Soong, David, additional, Qin, Xiang, additional, Sasser, Kate, additional, and Khokhar, Nushmia, additional

Published
2017
Full Text
View/download PDF

30. Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX

Author

San-Miguel, Jesus, primary, Dimopoulos, Meletios Athanasios, additional, Usmani, Saad, additional, Belch, Andrew R., additional, Bahlis, Nizar J., additional, White, Darrell J., additional, Benboubker, Lofti, additional, Cook, Gordon, additional, Leiba, Merav, additional, Morton, James, additional, Ho, P. Joy, additional, Kim, Kihyun, additional, Takezako, Naoki, additional, Kaufman, Jonathan L., additional, Sutherland, Heather, additional, Lalancette, Marc, additional, Magen, Hila, additional, Iida, Shinsuke, additional, Kim, Jin Seok, additional, Prince, H. Miles, additional, Cochrane, Tara, additional, Oriol, Albert, additional, Chari, Ajai, additional, Wu, Kaida, additional, and Casneuf, Tineke, additional

Published
2017
Full Text
View/download PDF

31. Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Author

Moreau, Philippe, primary, Kaufman, Jonathan L., additional, Sutherland, Heather J., additional, Lalancette, Marc, additional, Magen, Hila, additional, Iida, Shinsuke, additional, Kim, Jin Seok, additional, Prince, Miles, additional, Cochrane, Tara, additional, Khokhar, Nushmia Z, additional, Guckert, Mary, additional, Qin, Xiang, additional, and Oriol, Albert, additional

Published
2016
Full Text
View/download PDF

32. Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure

Author

Kim, Dennis Dong Hwan, primary, Savoie, Mary Lynn, additional, Bence-Bruckler, Isabelle, additional, Huebsch, Lothar B., additional, Lalancette, Marc, additional, Hillis, Christopher M., additional, Walker, Irwin, additional, Forrest, Donna L., additional, and Lipton, Jeff H., additional

Published
2016
Full Text
View/download PDF

33. Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

Author

Bahlis, Nizar J., primary, Kotb, Rami, additional, Sebag, Michael, additional, Sutherland, Heather J., additional, LeBlanc, Richard, additional, White, Darrell, additional, Venner, Christopher P., additional, Kouroukis, Tom, additional, Bergstrom, Debra, additional, McCurdy, Arleigh, additional, Lalancette, Marc, additional, Bensinger, William, additional, Lentzsch, Suzanne, additional, Del Col, Aldo, additional, Kauffman, Michael, additional, Shacham, Sharon, additional, Jeha, Jacqueline, additional, Picklesimer, Carla, additional, Saint-Martin, Jean-Richard, additional, Choe-Juliak, Cassandra, additional, and Chen, Christine, additional

Published
2016
Full Text
View/download PDF

34. Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Author

Chen, Christine, primary, Kotb, Rami, additional, Sebag, Michael, additional, LeBlanc, Richard, additional, Sutherland, Heather J., additional, White, Darrell, additional, Venner, Christopher P., additional, Kouroukis, Tom, additional, Bergstrom, Debra, additional, McCurdy, Arleigh, additional, Lalancette, Marc, additional, Bensinger, William, additional, Lentzsch, Suzanne, additional, Del Col, Aldo, additional, Kauffman, Michael, additional, Shacham, Sharon, additional, Jeha, Jacqueline, additional, Picklesimer, Carla, additional, Saint-Martin, Jean-Richard, additional, Choe-Juliak, Cassandra, additional, and Bahlis, Nizar J., additional

Published
2016
Full Text
View/download PDF

38. Gravitational waves from a string cusp in Einstein-aether theory

Author

Lalancette, Marc

Abstract

The motivation of this thesis is to look for a signature of Lorentz violation, hopefully observable, in the gravitational waves emitted by cosmic strings. Aspects of cosmic strings are reviewed, in particular how focused bursts of gravitational radiation are emitted when a cusp forms on the string. The same phenomenon is then studied in an effective field theory with Lorentz violation called Einstein-aether theory. This is a simple theory with a dynamic preferred frame, but it retains rotational and diffeomorphism invariance. The linearized version of the theory produces five wave modes. We study the usual transverse traceless modes which now have a wave speed that can be lower or greater than the speed of light. This altered speed produces distinctive features in the waves. They depend on two free parameters: roughly the wave speed and the acceleration of the string cusp. The profile of the wave is analyzed in detail for different values of the parameters and explained by close comparison with the string motion.

Published
2008
Full Text
View/download PDF

39. Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Author

Moreau, Philippe, Oriol, Albert, Kaufman, Jonathan L., Sutherland, Heather, Lalancette, Marc, Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Prince, Miles, Cochrane, Tara, O'Rourke, Lisa, Wu, Kaida, Schecter, Jordan M., and Bahlis, Nizar J.

Published
2017
Full Text
View/download PDF

40. Adjuvant treatment for endometrial cancer: Literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)

Author

Morneau, Mélanie, primary, Foster, William, additional, Lalancette, Marc, additional, Van Nguyen-Huynh, Thu, additional, Renaud, Marie-Claude, additional, Samouëlian, Vanessa, additional, Letarte, Nathalie, additional, Almanric, Karine, additional, Boily, Gino, additional, Bouchard, Philippe, additional, Boulanger, Jim, additional, Cournoyer, Ghislain, additional, Couture, Félix, additional, Gervais, Normand, additional, Goulet, Stéphanie, additional, Guay, Marie-Pascale, additional, Kavanagh, Mélanie, additional, Lemieux, Julie, additional, Lespérance, Bernard, additional, Morneau, Mélanie, additional, Ouellet, Jean-François, additional, Pineau, Gilles, additional, Rajan, Raghu, additional, Roy, Isabelle, additional, Samson, Benoît, additional, Sidéris, Lucas, additional, and Vincent, François, additional

Published
2013
Full Text
View/download PDF

43. Pour une sémiotique du vêtement : étude socio-idéologique du phénomène vestimentaire en contexte occidental

Author

Lalancette, Marc, Lacasse, Rodolphe, Lalancette, Marc, and Lacasse, Rodolphe

Abstract

Ce que nous proposons ici comme recherche est d'effectuer une étude du phénomène vestimentaire fidèle à l'approche sémiotique définie par Umberto Eco. Aussi utiliserons-nous dorénavant le terme "sémiotique" (par opposition à la "sémiologie" de Barthes) conformément à la position que nous avons adoptée. Mettre sur pied une complète sémiotique du vêtement serait une entreprise surhumaine. En effet, le phénomène a pris une telle ampleur autant psychologiquement que socialement et historiquement que toute prétention à l'exhaustivité serait forcément inconséquente. Aussi devons-nous spécifier les buts que nous désirons atteindre ainsi que les limites de cette étude. Premièrement, nous désirons réaliser la contrepartie du Système de la Mode de R. Barthes en faisant une étude du vêtement en tant que processus de communication culturelle. Nous postulons que la culture communique aux hommes à travers le vêtement et nous voulons établir la nature du message qu'elle transmet ainsi que celle des codes qu'elle utilise. Nous croyons donc que derrière ce phénomène innocent en apparence qu'est le vêtement se dresse tout un système que nous voulons sortir de l'anonymat. Il va sans dire que nous effectuons cette recherche non pour le simple plaisir de la controverse mais bien parce que nous sommes convaincu (et désirons en convaincre d'autres) de la légitimité de l'approche sémiotique de Eco et que nous voulons l'illustrer d'un exemple décisif. Contribuer à une sémiotique du vêtement est ainsi le but externe (global, général) de notre recherche. Deuxièmement, le but interne (spécifique) de notre étude est de démontrer qu'en communiquant à travers le vêtement la culture lui imprime sa forme et, par conséquent, en influence irrémédiablement la perception. Il n'est donc pas question ici d'établir un dictionnaire des significations vestimentaires mais bien d'analyser le fonctionnement d'un phénomène culturel.

Published
1982

44. Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.

Author

Laverdière I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socié G, and Lévesque É

Subjects
Acute Disease, Adult, Canada epidemiology, Chronic Disease, Cohort Studies, Female, Follow-Up Studies, Graft vs Host Disease epidemiology, Graft vs Host Disease mortality, Hematologic Neoplasms complications, Hematologic Neoplasms mortality, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Immunosuppressive Agents therapeutic use, Incidence, Male, Middle Aged, Neoplasm Staging, Prognosis, Survival Rate, Young Adult, Biomarkers, Tumor genetics, Cyclosporine therapeutic use, Graft vs Host Disease drug therapy, Graft vs Host Disease genetics, Methotrexate therapeutic use, Pharmacogenetics, Polymorphism, Single Nucleotide genetics
Abstract

Effective immunosuppression is mandatory to prevent graft-versus-host disease and to achieve a successful clinical outcome of hematopoietic stem cell transplantation. Here we tested whether germline single nucleotide polymorphisms in 20 candidate genes related to methotrexate and cyclosporine metabolism and activity influence the incidence of graft-versus-host disease in patients who undergo stem cell transplantation for hematologic disorders. Recipient genetic status of the adenosine triphosphate-binding cassette sub-family C1 and adenosine triphosphate-binding cassette sub-family C2 transporters, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/ inosine monophosphate cyclohydrolase within the methotrexate pathway, and nuclear factor of activated T cells (cytoplasmic 1) loci exhibit a remarkable influence on severe acute graft-versus-host disease prevalence. Indeed, an increased risk of acute graft-versus-host disease was observed in association with single nucleotide polymorphisms located in 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (hazard ratio=3.04; P=0.002), nuclear factor of activated T cells (cytoplasmic 1) (hazard ratio=2.69; P=0.004), adenosine triphosphate-binding cassette sub-family C2 (hazard ratio=3.53; P=0.0018) and adenosine triphosphate-binding cassette sub-family C1 (hazard ratio=3.67; P=0.0005). While donor single nucleotide polymorphisms of dihydrofolate reductase and solute carrier family 19 (member 1) genes are associated with a reduced risk of acute graft-versus-host disease (hazard ratio=0.32-0.41; P=0.0009-0.008), those of nuclear factor of activated T cells (cytoplasmic 2) are found to increase such risk (hazard ratio=3.85; P=0.0004). None of the tested single nucleotide polymorphisms was associated with the occurrence of chronic graft-versus-host disease. In conclusion, by targeting drug-related biologically relevant genes, this work emphasizes the potential role of germline biomarkers in predicting acute graft-versus-host disease. Further investigations are warranted to improve our understanding of these relationships to personalize immunosuppressive therapy and optimize outcomes., (Copyright© Ferrata Storti Foundation.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results